These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 32145658)

  • 1. Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock.
    Tchen S; Sullivan JB
    J Crit Care; 2020 Jun; 57():148-156. PubMed ID: 32145658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catecholamine Vasopressor Support Sparing Strategies in Vasodilatory Shock.
    Buckley MS; Barletta JF; Smithburger PL; Radosevich JJ; Kane-Gill SL
    Pharmacotherapy; 2019 Mar; 39(3):382-398. PubMed ID: 30506565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylene blue, midodrine, and pseudoephedrine: a review of alternative agents for refractory hypotension in the intensive care unit.
    Van Berkel MA; Fuller LA; Alexandrov AW; Jones GM
    Crit Care Nurs Q; 2015; 38(4):345-58. PubMed ID: 26335214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock.
    Whitson MR; Mo E; Nabi T; Healy L; Koenig S; Narasimhan M; Mayo PH
    Chest; 2016 Jun; 149(6):1380-3. PubMed ID: 26953217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).
    Anstey MH; Wibrow B; Thevathasan T; Roberts B; Chhangani K; Ng PY; Levine A; DiBiasio A; Sarge T; Eikermann M
    BMC Anesthesiol; 2017 Mar; 17(1):47. PubMed ID: 28327122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midodrine for the weaning of vasopressor infusions.
    Poveromo LB; Michalets EL; Sutherland SE
    J Clin Pharm Ther; 2016 Jun; 41(3):260-5. PubMed ID: 26945564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of methylene blue in refractory septic shock: study protocol for a multicenter, randomized, placebo-controlled trial.
    Jia J; Ji J; Liu Z
    Trials; 2024 Sep; 25(1):630. PubMed ID: 39334256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of methylene blue for refractory septic shock during continuous venovenous hemodiafiltration.
    Mount JC; Rowe AS
    Pharmacotherapy; 2010 Mar; 30(3):323. PubMed ID: 20180614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does methylene blue administration to septic shock patients affect vascular permeability and blood volume?
    Donati A; Conti G; Loggi S; Münch C; Coltrinari R; Pelaia P; Pietropaoli P; Preiser JC
    Crit Care Med; 2002 Oct; 30(10):2271-7. PubMed ID: 12394955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Putting midodrine on the MAP: An approach to liberation from intravenous vasopressors in vasodilatory shock.
    Smith SE; Peters NA; Floris LM; Patterson JM; Hawkins WA
    Am J Health Syst Pharm; 2022 Jun; 79(13):1047-1055. PubMed ID: 35235946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressor-Sparing Action of Methylene Blue in Severe Sepsis and Shock: A Narrative Review.
    Puntillo F; Giglio M; Pasqualucci A; Brienza N; Paladini A; Varrassi G
    Adv Ther; 2020 Sep; 37(9):3692-3706. PubMed ID: 32705530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock.
    Albertson TE; Chenoweth JA; Lewis JC; Pugashetti JV; Sandrock CE; Morrissey BM
    Expert Rev Clin Pharmacol; 2022 Aug; 15(8):959-976. PubMed ID: 35920615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylene Blue Reduces Mortality in Critically Ill and Perioperative Patients: A Meta-Analysis of Randomized Trials.
    Pruna A; Bonaccorso A; Belletti A; Turi S; Di Prima AL; D'amico F; Zangrillo A; Kotani Y; Landoni G
    J Cardiothorac Vasc Anesth; 2024 Jan; 38(1):268-274. PubMed ID: 37880041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions.
    Levine AR; Meyer MJ; Bittner EA; Berg S; Kalman R; Stanislaus AB; Ryan C; Ball SA; Eikermann M
    J Crit Care; 2013 Oct; 28(5):756-62. PubMed ID: 23845791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of methylene blue in septic shock: pros and cons.
    Arias-Ortiz J; Vincent JL
    Crit Care; 2024 Feb; 28(1):46. PubMed ID: 38365828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylene blue for the treatment of septic shock.
    Paciullo CA; McMahon Horner D; Hatton KW; Flynn JD
    Pharmacotherapy; 2010 Jul; 30(7):702-15. PubMed ID: 20575634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Adrenergic Vasopressors in Patients with or at Risk for Vasodilatory Shock. A Systematic Review and Meta-Analysis of Randomized Trials.
    Belletti A; Musu M; Silvetti S; Saleh O; Pasin L; Monaco F; Hajjar LA; Fominskiy E; Finco G; Zangrillo A; Landoni G
    PLoS One; 2015; 10(11):e0142605. PubMed ID: 26558621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midodrine therapy for vasopressor dependent shock in the intensive care unit: a protocol for a systematic review and meta-analysis.
    Kamaleldin M; Kilcommons S; Opgenorth D; Fiest K; Karvellas CJ; Kutsogiannis J; Lau V; MacIntyre E; Rochwerg B; Senaratne J; Slemko J; Sligl W; Wang X; Bagshaw SM; Rewa OG
    BMJ Open; 2022 Nov; 12(11):e064060. PubMed ID: 36418124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodal strategy to counteract vasodilation in septic shock.
    Leone M; Einav S; Antonucci E; Depret F; Lakbar I; Martin-Loeches I; Wieruszewski PM; Myatra SN; Khanna AK
    Anaesth Crit Care Pain Med; 2023 Jun; 42(3):101193. PubMed ID: 36621622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LIBERATE: a study protocol for midodrine for the early liberation from vasopressor support in the intensive care unit (LIBERATE): protocol for a randomized controlled trial.
    Opgenorth D; Baig N; Fiest K; Karvellas C; Kutsogiannis J; Lau V; Macintyre E; Senaratne J; Slemko J; Sligl W; Wang X; Bagshaw SM; Rewa OG
    Trials; 2022 Mar; 23(1):194. PubMed ID: 35246227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.